[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) – Form 4 insider activity: Director and 10% owner Richard Ian Griffiths, through Cream Capital Ltd., reported two open-market purchases of American Depositary Shares (ADS).

• 31 Jul 2025: 14,342 ADS at $6.18
• 1 Aug 2025: 4,034 ADS at $6.14

The combined 18,376 ADS cost roughly $113 k and lifted his indirect holding to 11,825,861 ADS. Each ADS converts into three ordinary shares and has no expiration date. Griffiths disclaims beneficial ownership beyond his pecuniary interest.

The transactions modestly increase an already large position (<0.02 % incremental) and do not affect control status, but fresh insider buying can be viewed as a mild vote of confidence. No sales, options, or other derivative moves were disclosed.

Positive

• Insider accumulation: 10% owner purchased 18,376 ADS, signalling incremental confidence.

Negative

• Immaterial size: Purchases represent less than 0.02 % of existing stake, limiting market impact.

Insights

Securities Analyst

TL;DR: Small incremental buy by major holder; sentiment slightly positive but financially immaterial.

The purchase totalling 18,376 ADS (~$113 k) is negligible versus Griffiths’ 11.8 million-unit stake and therefore does not change the ownership landscape or imply a material capital commitment. However, continued accumulation by a 10 % owner—executed in the open market rather than via option exercise—often serves as a behavioral signal of confidence in future prospects. The absence of any dispositions or hedging activity keeps the reading neutral-to-positive. From a liquidity standpoint, the trade size is unlikely to influence share supply-demand dynamics. Overall impact on valuation or governance risk is minimal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

FLOOR 1 LIBERATION STATION

ESPLANADE

(Street)

ST HELIER Y9 JE2 3AS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$6.18	07/31/2025		P		14,342		(1)	(1)	Ordinary Shares	43,026	(1)	11,821,827	I	See footnote(2)
American Depositary Shares	$6.14	08/01/2025		P		4,034		(1)	(1)	Ordinary Shares	12,102	(1)	11,825,861	I	See footnote(2)

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

2. The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

	/s/ Richard Ian Griffiths	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Griffiths purchase?

He bought 18,376 American Depositary Shares across two days.

At what prices were the SLN ADS purchased?

$6.18 on 31 Jul 2025 for 14,342 ADS and $6.14 on 1 Aug 2025 for 4,034 ADS.

What is Griffiths’ total SLN ADS ownership after these transactions?

He indirectly holds 11,825,861 ADS through Cream Capital Ltd.

How many ordinary shares do the purchased ADS represent?

Each ADS equals three ordinary shares, so the 18,376 ADS correspond to 55,128 ordinary shares.

Does the Form 4 disclose any share sales or option exercises?

No. The filing lists only open-market purchases; no dispositions or option activity are reported.